Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback